Recommendation for Persistent Elevated Red Blood Cell Count
Test for JAK2 mutation (V617F and exon 12) and measure serum erythropoietin level as the initial diagnostic workup to distinguish polycythemia vera from secondary causes of erythrocytosis 1.
Diagnostic Algorithm
Step 1: Confirm True Erythrocytosis
Repeat complete blood count to verify persistent elevation. True erythrocytosis is defined as:
- Hemoglobin ≥18.5 g/dL in men or ≥16.5 g/dL in women
- Hematocrit ≥49% in men or ≥48% in women 1
Step 2: Initial Laboratory Testing
Order these two tests simultaneously:
- JAK2 mutation analysis (V617F and exon 12 mutations) - present in ~95% of polycythemia vera cases 1
- Serum erythropoietin level - subnormal in polycythemia vera, normal or elevated in secondary causes 2
Step 3: Interpretation and Next Steps
If JAK2 positive + low erythropoietin:
- Proceed with bone marrow biopsy to confirm polycythemia vera diagnosis 1
- Diagnosis requires both major criteria (elevated hemoglobin AND JAK2 mutation) plus one minor criterion (bone marrow hypercellularity with panmyelosis, low erythropoietin, or endogenous erythroid colonies) 1
If JAK2 negative + normal/elevated erythropoietin:
- Evaluate for secondary causes:
- Hypoxia-related: Obtain pulse oximetry, arterial blood gas, chest imaging for cardiopulmonary disease 3, 2
- Renal causes: Renal ultrasound with Doppler for renal artery stenosis, imaging for renal cell carcinoma 3
- Medication review: Specifically ask about testosterone, SGLT2 inhibitors, erythropoiesis-stimulating agents 3
- Congenital causes (if lifelong history): Consider high-oxygen-affinity hemoglobin variants, EPOR mutations, oxygen-sensing pathway mutations 3, 2
If JAK2 negative + low erythropoietin:
- Consider expanded genetic testing for hereditary erythrocytosis (EPOR, PIEZO1, HIF2A, PHD2, VHL mutations) 3
- May still represent early polycythemia vera with low mutation burden - consider bone marrow biopsy 1
Management Considerations
For Confirmed Polycythemia Vera:
Risk stratification determines treatment intensity:
- All patients: Low-dose aspirin, cardiovascular risk factor management 4
- High-risk patients (age >60 or prior thrombosis): Add cytoreductive therapy with hydroxyurea as first-line 4
- Low-risk patients: Phlebotomy to maintain hematocrit <45% in men, <42% in women, plus aspirin 4
For Secondary Erythrocytosis:
- Treat the underlying cause - this is paramount 5
- Avoid cytoreductive therapy - not indicated for secondary causes 3
- Consider phlebotomy only for symptom control if hematocrit remains severely elevated despite treating underlying cause 3
- Low-dose aspirin and cardiovascular risk optimization may be reasonable 3
Critical Pitfalls to Avoid
Do not assume relative/spurious polycythemia without proper workup - this represents volume contraction, not true erythrocytosis 3. Your patient's lack of smoking history makes secondary causes from chronic hypoxia less likely but doesn't exclude other etiologies.
Do not order red cell mass measurement as initial testing - this has been replaced by JAK2 mutation analysis in modern diagnostic algorithms 2. The genetic approach is more specific and cost-effective.
Do not delay JAK2 testing - approximately 5% of polycythemia vera cases have exon 12 mutations rather than V617F, so both must be tested 1.
Iron deficiency can mask polycythemia vera - if ferritin is low, the hemoglobin may not meet diagnostic thresholds. However, in clinical practice, you can make a working diagnosis if other criteria are met, though formal research diagnosis requires demonstrating elevated hemoglobin after iron replacement 1.
The absence of snoring makes obstructive sleep apnea less likely as a secondary cause, and no smoking history reduces probability of chronic obstructive pulmonary disease, but these must still be formally excluded through objective testing if JAK2 is negative 3.